Asia Pacific Multi-cancer Early Detection Market Size, Share & Trends Analysis Report By Type (Liquid Biopsy, Gene Panel, LDT ), By End-use (Hospitals, Diagnostic Laboratories), By Region, And Segment Forecasts, 2023 - 2030

Table of Contents

Chapter 1. Methodology and Scope
                    1.1. Market Segmentation and Scope
                    1.2. Market Definitions
                        1.2.1. Type Segment
                        1.2.2. End-use Segment
                    1.3. Regional Scope
                    1.4. Estimates and Forecast Timeline
                    1.5. Objectives
                        1.5.1. Objective - 1
                        1.5.2. Objective - 2
                        1.5.3. Objective - 3
                    1.6. Research Methodology
                    1.7. Information Procurement
                        1.7.1. Purchased Database
                        1.7.2. GVR’s Internal Database
                        1.7.3. Secondary Sources
                        1.7.4. Primary Research
                    1.8. Information or Data Analysis
                        1.8.1. Data Analysis Models
                    1.9. Market Formulation & Validation
                    1.10. Model Details
                        1.10.1. Commodity Flow Analysis
                    1.11. List of Secondary Sources
                    1.12. List of Abbreviations
Chapter 2. Executive Summary
                    2.1. Market Snapshot
                    2.2. Type and End-use Snapshot
                    2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
                    3.1. Market Lineage Outlook
                        3.1.1. Parent Market Outlook
                        3.1.2. Related/Ancillary Market Outlook
                    3.2. Market Dynamics
                        3.2.1. Market Driver Analysis
                            3.2.1.1. Increasing prevalence of cancer
                            3.2.1.2. Extensive R&D for the development of MCED
                            3.2.1.3. Need to develop diagnostic options that can detect cancer at an early stage
                        3.2.2. Market Restraint Analysis
                            3.2.2.1. Collection of adequate safety and efficacy data for regulatory approval
                        3.2.3. Challenges Analysis
                        3.2.4. Opportunity Analysis
                    3.3. SWOT Analysis, by Factor
                    3.4. Industry Analysis- Porter’s
Chapter 4. Type Business Analysis
                    4.1. Asia Pacific Multi-cancer Early Detection Market: Type Movement Analysis
                    4.2. Liquid Biopsy
                        4.2.1. Liquid Biopsy Market, 2018 - 2030 (USD Million)
                    4.3. Gene Panel, LDT, and Others
                        4.3.1. Gene Panel, LDT, and Others Market, 2018 - 2030 (USD Million)
Chapter 5. End-Use Business Analysis
                    5.1. Asia Pacific Multi-cancer Early Detection Market: End-Use Movement Analysis
                    5.2. Hospitals
                        5.2.1. Hospitals Market, 2018 - 2030 (USD Million)
                    5.3. Diagnostic Laboratories
                        5.3.1. Diagnostic Laboratories Market, 2018 - 2030 (USD Million)
                    5.4. Others
                        5.4.1. Others Market, 2018 - 2030 (USD Million)
Chapter 6. Regional Business Analysis
                    6.1. Asia Pacific Multi-cancer Early Detection Market Share By Region, 2022 & 2030
                    6.2. Asia Pacific
                        6.2.1. SWOT Analysis
                        6.2.2. Asia Pacific Multi-cancer Early Detection Market, 2018 - 2030 (USD Million)
                        6.2.3. Japan
                            6.2.3.1. Key Country Dynamics
                            6.2.3.2. Target Disease Prevalence
                            6.2.3.3. Competitive Scenario
                            6.2.3.4. Regulatory Framework
                            6.2.3.5. Japan Multi-Cancer Early Detection Market, 2018 - 2030 (USD Million)
                        6.2.4. China
                            6.2.4.1. Key Country Dynamics
                            6.2.4.2. Target Disease Prevalence
                            6.2.4.3. Competitive Scenario
                            6.2.4.4. Regulatory Framework
                            6.2.4.5. China Multi-Cancer Early Detection Market, 2018 - 2030 (USD Million)
                        6.2.5. India
                            6.2.5.1. Key Country Dynamics
                            6.2.5.2. Target Disease Prevalence
                            6.2.5.3. Competitive Scenario
                            6.2.5.4. Regulatory Framework
                            6.2.5.5. India Multi-Cancer Early Detection Market, 2018 - 2030 (USD Million)
                        6.2.6. South Korea
                            6.2.6.1. Key Country Dynamics
                            6.2.6.2. Target Disease Prevalence
                            6.2.6.3. Competitive Scenario
                            6.2.6.4. Regulatory Framework
                            6.2.6.5. South Korea Multi-Cancer Early Detection Market, 2018 - 2030 (USD Million)
                        6.2.7. Australia
                            6.2.7.1. Key Country Dynamics
                            6.2.7.2. Target Disease Prevalence
                            6.2.7.3. Competitive Scenario
                            6.2.7.4. Regulatory Framework
                            6.2.7.5. Australia Multi-Cancer Early Detection Market, 2018 - 2030 (USD Million)
                        6.2.8. Thailand
                            6.2.8.1. Key Country Dynamics
                            6.2.8.2. Target Disease Prevalence
                            6.2.8.3. Competitive Scenario
                            6.2.8.4. Regulatory Framework
                            6.2.8.5. Thailand Multi-Cancer Early Detection Market, 2018 - 2030 (USD Million)
                        6.2.9. Singapore
                            6.2.9.1. Key Country Dynamics
                            6.2.9.2. Target Disease Prevalence
                            6.2.9.3. Competitive Scenario
                            6.2.9.4. Regulatory Framework
                            6.2.9.5. Singapore Multi-Cancer Early Detection Market, 2018 - 2030 (USD Million)
                        6.2.10. Taiwan
                            6.2.10.1. Key Country Dynamics
                            6.2.10.2. Target Disease Prevalence
                            6.2.10.3. Competitive Scenario
                            6.2.10.4. Regulatory Framework
                            6.2.10.5. Taiwan Multi-Cancer Early Detection Market, 2018 - 2030 (USD Million)
                        6.2.11. Hong Kong
                            6.2.11.1. Key Country Dynamics
                            6.2.11.2. Target Disease Prevalence
                            6.2.11.3. Competitive Scenario
                            6.2.11.4. Regulatory Framework
                            6.2.11.5. Hong Kong Multi-Cancer Early Detection Market, 2018 - 2030 (USD Million)
                        6.2.12. Rest of APAC
                            6.2.12.1. Key Country Dynamics
                            6.2.12.2. Target Disease Prevalence
                            6.2.12.3. Competitive Scenario
                            6.2.12.4. Regulatory Framework
                            6.2.12.5. Rest of APAC Multi-Cancer Early Detection Market, 2018 - 2030 (USD Million)
Chapter 7. Competitive Landscape
                    7.1. Company Categorization
                    7.2. Strategy Mapping
                    7.3. Company Market Share Analysis, 2022
                    7.4. Company Profiles/Listing
                        7.4.1. Grail, LLC (Illumina, Inc.)
                            7.4.1.1. Overview
                            7.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                            7.4.1.3. Product Benchmarking
                            7.4.1.4. Strategic Initiatives
                        7.4.2. Exact Sciences Corporation
                            7.4.2.1. Overview
                            7.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                            7.4.2.3. Product Benchmarking
                            7.4.2.4. Strategic Initiatives
                        7.4.3. AnchorDx
                            7.4.3.1. Overview
                            7.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                            7.4.3.3. Product Benchmarking
                            7.4.3.4. Strategic Initiatives
                        7.4.4. Guardant Health
                            7.4.4.1. Overview
                            7.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                            7.4.4.3. Product Benchmarking
                            7.4.4.4. Strategic Initiatives
                        7.4.5. Burning Rock Biotech Limited
                            7.4.5.1. Overview
                            7.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                            7.4.5.3. Product Benchmarking
                            7.4.5.4. Strategic Initiatives
                        7.4.6. GENECAST
                            7.4.6.1. Overview
                            7.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                            7.4.6.3. Product Benchmarking
                            7.4.6.4. Strategic Initiatives
                        7.4.7. Singlera Genomics Inc.
                            7.4.7.1. Overview
                            7.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                            7.4.7.3. Product Benchmarking
                            7.4.7.4. Strategic Initiatives
                        7.4.8. Laboratory for Advanced Medicine, Inc.
                            7.4.8.1. Overview
                            7.4.8.2. Product Benchmarking
                            7.4.8.3. Strategic Initiatives
                        7.4.9. MiRXES Pte Ltd.
                            7.4.9.1. Overview
                            7.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                            7.4.9.3. Product Benchmarking
                            7.4.9.4. Strategic Initiatives

List of Tables

Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Funding by Organizations
Table 4 Asia Pacific Multi-cancer Early Detection Market, By Country, 2018 - 2030 (USD Million)
Table 5 Asia Pacific Multi-cancer Early Detection Market, By Type, 2018 - 2030 (USD Million)
Table 6 Asia Pacific Multi-cancer Early Detection Market, By End-Use, 2018 - 2030 (USD Million)
Table 7 Japan Multi-Cancer Early Detection Market, By Type, 2018 - 2030 (USD Million)
Table 8 Japan Multi-Cancer Early Detection Market, By End-Use, 2018 - 2030 (USD Million)
Table 9 China Multi-Cancer Early Detection Market, By Type, 2018 - 2030 (USD Million)
Table 10 China Multi-Cancer Early Detection Market, By End-Use, 2018 - 2030 (USD Million)
Table 11 India Multi-Cancer Early Detection Market, By Type, 2018 - 2030 (USD Million)
Table 12 India Multi-Cancer Early Detection Market, By End-Use, 2018 - 2030 (USD Million)
Table 13 Thailand Multi-Cancer Early Detection Market, By Type, 2018 - 2030 (USD Million)
Table 14 Thailand Multi-Cancer Early Detection Market, By End-Use, 2018 - 2030 (USD Million)
Table 15 South Korea Multi-Cancer Early Detection Market, By Type, 2018 - 2030 (USD Million)
Table 16 South Korea Multi-Cancer Early Detection Market, By End-Use, 2018 - 2030 (USD Million)
Table 17 Australia Multi-Cancer Early Detection Market, By Type, 2018 - 2030 (USD Million)
Table 18 Australia Multi-Cancer Early Detection Market, By End-Use, 2018 - 2030 (USD Million)
Table 19 Singapore Multi-Cancer Early Detection Market, By Type, 2018 - 2030 (USD Million)
Table 20 Singapore Multi-Cancer Early Detection Market, By End-Use, 2018 - 2030 (USD Million)
Table 21 Taiwan Multi-Cancer Early Detection Market, By Type, 2018 - 2030 (USD Million)
Table 22 Taiwan Multi-Cancer Early Detection Market, By End-Use, 2018 - 2030 (USD Million)
Table 23 Hong Kong Multi-Cancer Early Detection Market, By Type, 2018 - 2030 (USD Million)
Table 24 Hong Kong Multi-Cancer Early Detection Market, By End-Use, 2018 - 2030 (USD Million)
Table 25 Rest of APAC Multi-Cancer Early Detection Market, By Type, 2018 - 2030 (USD Million)
Table 26 Rest of APAC Multi-Cancer Early Detection Market, By End-Use, 2018 - 2030 (USD Million)
Table 27 Company Market Share, 2022

List of Figures

Fig. 1 Market Research Process
Fig. 2 Information Procurement
Fig. 3 Primary Research Pattern
Fig. 4 Market Research Approaches
Fig. 5 Value Chain-Based Sizing & Forecasting
Fig. 6 Market Formulation & Validation
Fig. 7 Asia Pacific Multi-cancer Early Detection Market Segmentation
Fig. 8 Market Driver Relevance Analysis (Current & Future Impact)
Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
Fig. 10 Market Challenge Relevance Analysis (Current & Future Impact)
Fig. 11 Penetration & Growth Prospect Mapping
Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
Fig. 13 Porter’s Five Forces Analysis
Fig. 14 Asia Pacific multi-cancer early detection market: Type outlook and key takeaways
Fig. 15 Asia Pacific multi-cancer early detection market: Type movement analysis & market share 2022 & 2030
Fig. 16 Liquid biopsy market, 2018 - 2030 (USD Million)
Fig. 17 Gene panel, LDT, & others market, 2018 - 2030 (USD Million)
Fig. 18 Asia Pacific multi-cancer early detection market: End-use outlook and key takeaways
Fig. 19 Asia Pacific multi-cancer early detection market: End-use movement analysis & market share 2022 & 2030
Fig. 20 Hospitals market, 2018 - 2030 (USD Million)
Fig. 21 Diagnostic laboratories market, 2018 - 2030 (USD Million)
Fig. 22 Others market, 2018 - 2030 (USD Million)
Fig. 23 Asia Pacific, SWOT Analysis
Fig. 24 Asia Pacific
Fig. 25 Asia Pacific Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 26 Japan
Fig. 27 Japan Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 28 China
Fig. 29 China Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 30 India
Fig. 31 India Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 32 Thailand
Fig. 33 Thailand Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 34 South Korea
Fig. 35 South Korea Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 36 Australia
Fig. 37 Australia Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 38 Singapore
Fig. 39 Singapore Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 40 Taiwan
Fig. 41 Taiwan Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 42 Hong Kong
Fig. 43 Hong Kong Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 44 Rest of APAC
Fig. 45 Rest of APAC Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 46 Strategy Mapping